Merck (MRK) is said to reorganise its main Pharma unit and form a separate cancer unity, WSJ reports

Merck (MRK) is said to reorganise its main Pharma unit and form a separate cancer unity, WSJ reports.

Merck's decision to reorganize its main Pharma unit and create a separate cancer unit could signal a strategic shift aimed at enhancing focus on oncology, a sector that has seen significant growth and investment. This move may also attract attention from investors looking for specialized growth opportunities within pharmaceuticals, potentially impacting the company's stock performance and broader market sentiment towards the sector.